1. Preface

   • David. S. Alberts
   • David. Caldwell

   EditorialNotes Pages: 79 - 79

2. Editorial

   • David S. Alberts

   EditorialNotes Pages: 8181 - 8181

3. Development of mitoxantrone

   • Richard J. White
   • Frederick E. Durr

   OriginalPaper Pages: 85 - 93

4. Mitoxantrone: Propensity for free radical formation and lipid peroxidation — implications for cardiotoxicity

   • Raymond F. Novak
   • Evan D. Kharasch

   OriginalPaper Pages: 95 - 99

5. Pharmacology of mitoxantrone: mode of action and pharmacokinetics

   • David S. Alberts
   • Yei Mei Peng
   • Cindy Mackel

   OriginalPaper Pages: 101 - 107

6. The pharmacokinetics and metabolism of mitoxantrone in man

   • Gerhard Ehninger
   • Barbara Proksch
   • David L. Woodward

   OriginalPaper Pages: 109 - 116

7. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update

   • Robert S. Benjamin
   • Sant P. Chawla
   • Frankie Holmes

   OriginalPaper Pages: 117 - 121

8. Mitoxantrone: an overview of safety and toxicity

   • Larry E. Posner
   • Gary Dukart
   • Kenneth Cartwright

   OriginalPaper Pages: 123 - 132

9. Mitoxantrone as a first-line treatment of advanced breast cancer

   • Karl Landys
   • Stig Borgstrom
   • Henry Noppa

   OriginalPaper Pages: 133 - 137

10. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study

    • H. T. Mouridsen
    • Michael Cornbleet
    • John Smyth

    OriginalPaper Pages: 139 - 148

11. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study)

    • John D. Cowan
    • C. Kent Osborne
    • Clarence B. Vaughn

    OriginalPaper Pages: 149 - 152

12. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer

    • Joseph C. Allegra
    • T. Woodcock
    • Gary Dukart

    OriginalPaper Pages: 153 - 161

13. Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer

    • R. Metz
    • M. Delgado
    • G. Mathe

    OriginalPaper Pages: 163 - 166

14. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer

    • P. Periti
    • G. Robustelli Delia Cuna
    • E. Mini

    OriginalPaper Pages: 167 - 171

15. Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity

    • Timothy J. Perren
    • George Blackledge
    • A. Hancock

    OriginalPaper Pages: 173 - 177

16. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

    • John M. Bennett
    • Patrick Byrne
    • Gary Dukart

    OriginalPaper Pages: 179 - 185

17. Phase II studies of mitoxantrone in patients with primary liver cancer

    • Geoffrey Falkson
    • Barend Johannes Coetzer

    OriginalPaper Pages: 187 - 189

18. Mitoxantrone in refractory acute leukemia in children: A phase I study

    • Kenneth A. Starling
    • Arlynn Faye Mulne
    • Gary Dukart

    OriginalPaper Pages: 191 - 195

19. A phase II study of mitoxantrone in acute leukemia

    • Tohru Masaoka
    • Hirotoshi Shibata
    • Hiroya Kawagoe

    OriginalPaper Pages: 197 - 201

20. Mitoxantrone in the treatment of relapsed and refractory acute leukemia

    • P. Meyer
    • A. D. Ho
    • E. Seither

    OriginalPaper Pages: 203 - 206

21. Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia

    • H. G. Prentice
    • J. Z. Wimperis
    • G. Robbins

    OriginalPaper Pages: 207 - 212

22. Phase I–II trial of mitoxantrone in acute leukemia: an interim report

    • Zalmen A. Arlin
    • Gary Dukart
    • The Lederle Cooperative Group

    OriginalPaper Pages: 213 - 217

23. Mitoxantrone in malignant lymphoma

    • Richard A. Gams
    • Shelley Bryan
    • Richard Stein

    OriginalPaper Pages: 219 - 222